The role of BMI1 in endometrial cancer and other cancers

Gene. 2023 Mar 10:856:147129. doi: 10.1016/j.gene.2022.147129. Epub 2022 Dec 20.

Abstract

Endometrial cancer (EC) is the third leading gynecological malignancy, and its treatment remains challenging. B cell-specific Moloney murine leukemia virus integration site-1 (BMI1) is one of the core members of the polycomb group (PcG) family, which plays a promoting role in the occurrence and development of various tumors. Notably, BMI1 has been found to be frequently upregulated in endometrial cancer (EC) and promote the occurrence of EC through promoting epithelial-mesenchymal transition (EMT) and AKT/PI3K pathways. This review summarizes the structure and upstream regulatory mechanisms of BMI1 and its role in EC. In addition, we focused on the role of BMI1 in chemoradiotherapy resistance and summarized the current drugs that target BMI1.

Keywords: BMI1; Chemoradiotherapy resistance; Overexpression; endometrial cancer (EC).

Publication types

  • Review

MeSH terms

  • Animals
  • Cell Transformation, Neoplastic / metabolism
  • Endometrial Neoplasms* / genetics
  • Epithelial-Mesenchymal Transition
  • Female
  • Humans
  • Mice
  • Phosphatidylinositol 3-Kinases*
  • Polycomb Repressive Complex 1 / genetics
  • Polycomb Repressive Complex 1 / metabolism
  • Polycomb-Group Proteins
  • Proto-Oncogene Proteins / genetics

Substances

  • Phosphatidylinositol 3-Kinases
  • Polycomb Repressive Complex 1
  • Polycomb-Group Proteins
  • BMI1 protein, human
  • Bmi1 protein, mouse
  • Proto-Oncogene Proteins